Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Braunstein retiring as Idorsia CMO

Plus: Lys names Vounatsos chair and updates from Theolytics, BeiGene, Renibus and MaaT

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 
March 23, 2024 12:24 AM UTC

After 15 years at Idorsia Ltd. (SIX:IDIA), Guy Braunstein will retire as CMO by the end of this month, after which he will continue as an adviser to the company. Antonio Olivieri will succeed Braunstein while remaining head of global medical affairs.

Lys Therapeutics S.A.S. named Michel Vounatsos as chair. Vounatsos was CEO of Biogen Inc. (NASDAQ:BIIB) in 2017-22. Lys is developing neurodegenerative and neurovascular diseases...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Beigene Ltd.

Idorsia Ltd.

Maat Pharma S.A.

Renibus Therapeutics Inc.

Theolytics Ltd.